Patients with myelofibrosis can see their quality of life impacted in a range of ways with various symptoms, said Ruben Mesa, MD, director of UT Health San Antonio MD Anderson Cancer Center.
Patients with myelofibrosis can see their quality of life impacted in a range of ways with various symptoms, said Ruben Mesa, MD, director of UT Health San Antonio MD Anderson Cancer Center.
Transcript
What is the quality of life like for patients with myelofibrosis? How does it negatively impact them?
Quality of life in patients with myelofibrosis is really impacted in a range of ways. You know, first, they can have a degree of cytopenia-related difficulties. With anemia, they can have shortness of breath, fatigue, they can have thrombocytopenia, have increased risk of bruising, bleeding, etc.
Second, there's a whole range of what we believe are cytokine-related symptoms that they have from the disease. That can be inadvertent weight loss, night sweats, cachexia itching, things of that nature.
Third, if the counter high they can have vascular-related side effects: difficulties with headaches, concentration, complex migraines, etc.
Next, they may have potentially difficulties related to their spleen issues. Patients can sometimes have massive splenomegaly and with that they can have early satiety, they can kind of worse in that disease-associated weight loss, or they can have pain, discomfort, and derivative to these, they can have a lot of difficulties with insomnia and things of that nature.
It's really a whole range of things. Overall, we find that almost 90% of patients with myelofibrosis are symptomatic from their disease, some of them in a very severe way. And the individual pattern of symptoms is obviously somewhat unique to each patient.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More